优化功能促进疗法临床试验设计以评估疗效
学术界、制药业、NIH和FDA专家讨论了功能促进疗法试验设计的优化,包括适应证框架、入选标准和终点。与衰老和慢性病相关的活动障碍是吸引人的适应证,其他功能受限情况包括急性病住院、癌症恶病质和跌倒损伤;需协调肌少症和衰弱定义,并联合多组分功能训练将药物诱导的肌肉量增加转化为功能改善。
要点
- 与衰老和慢性病相关的活动障碍被老年科医生认为是常见且与不良结局相关的状况,可可靠确认。
- 入选标准应兼顾选择有该状况的参与者和确保普遍性及招募便利性。
- 多组分功能训练整合平衡、稳定、力量和功能任务与认知行为策略,可能将药物诱导的肌肉量增加转化为功能改善。
核心结论
- 需要学术界、NIH、FDA、制药业、患者和专业学会合作,开展设计良好的功能促进药物试验,联合或不联合多组分功能训练。
研究设计与样本
- 来自学术界、制药业、美国国立卫生研究院(NIH)和美国食品药品监督管理局(FDA)的专家讨论了试验设计的优化,包括适应证框架、入选标准和终点。
主要发现
- 与衰老和慢性病相关的活动障碍是吸引人的适应证,因为老年科医生认为它是与不良结局相关的常见状况,且可可靠确认。
- 其他与老年人功能受限相关的状况包括急性病住院、癌症恶病质和跌倒损伤。
- 正在努力统一肌少症和衰弱的定义。
- 准确的肌肉量测量(如D3肌酸稀释法)可能是早期试验中的良好生物标志物。
- 基于表现和患者报告的躯体功能测量需要证明治疗是否改善人的生活、功能或感受。
关键数值与推荐
- 入选标准应协调选择有该状况的参与者与确保普遍性和招募便利性的目标。
- 多组分功能训练整合平衡、稳定、力量和功能任务与认知和行为策略,可能需要将药物诱导的肌肉量增加转化为功能改善。
临床怎么用
- 在早期试验中可考虑使用D3肌酸稀释法等准确测量肌肉量的生物标志物。
- 评估功能促进疗法时需结合基于表现和患者报告的躯体功能测量。
- 药物诱导的肌肉量增加可能需要联合多组分功能训练才能转化为功能改善。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several candidate molecules that may have application in treating physical limitations associated with aging and chronic diseases are in development. Challenges in the framing of indications, eligibility criteria, and endpoints and the lack of regulatory guidance have hindered the development of function-promoting therapies. METHODS: Experts from academia, pharmaceutical industry, National Institutes of Health (NIH), and Food and Drug Administration (FDA) discussed optimization of trial design including the framing of indications, eligibility criteria, and endpoints. RESULTS: Mobility disability associated with aging and chronic diseases is an attractive indication because it is recognized by geriatricians as a common condition associated with adverse outcomes, and it can be ascertained reliably. Other conditions associated with functional limitation in older adults include hospitalization for acute illnesses, cancer cachexia, and fall injuries. Efforts are underway to harmonize definitions of sarcopenia and frailty. Eligibility criteria should reconcile the goals of selecting participants with the condition and ensuring generalizability and ease of recruitment. An accurate measure of muscle mass (eg, D3 creatine dilution) could be a good biomarker in early-phase trials. Performance-based and patient-reported measures of physical function are needed to demonstrate whether treatment improves how a person lives, functions, or feels. Multicomponent functional training that integrates training in balance, stability, strength, and functional tasks with cognitive and behavioral strategies may be needed to translate drug-induced muscle mass gains into functional improvements. CONCLUSIONS: Collaborations among academic investigators, NIH, FDA, pharmaceutical industry, patients, and professional societies are needed to conduct well-designed trials of function-promoting pharmacological agents with and without multicomponent functional training.
引用
- Bhasin S, Cawthon PM, Correa-de-Araujo R, et al. Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies. J Gerontol A Biol Sci Med Sci. 2023. PMID: 37325959. doi:10.1093/gerona/glad024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。